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ABSTRACT 
Background 
Statin use after colorectal cancer diagnosis may improve survival but 
evidence from observational studies is conflicting. The anti-cancer effect of statins 
may be restricted to certain molecular subgroups. In this population-based cohort 
study the interaction between p53 and HMGCR expression, KRAS mutations, and 
the association between statin use and colon cancer survival was assessed. 
 
Methods 
The cohort consisted of 740 stage II and III colon cancer patients diagnosed 
between 2004-2008. Statin use was determined through clinical note review. Tissue 
blocks were retrieved to determine immunohistochemical expression of p53 and 
HMGCR in tissue microarrays and the presence of KRAS mutations in extracted 
DNA. Cox proportional hazards models were used to calculate hazard ratios (HR) 
and 95% confidence intervals (CI) for colorectal cancer-specific and overall survival. 
 
Results 
Statin use was not associated with improved cancer-specific survival in this 
cohort (HR=0.91, 95% CI 0.64-1.28). Statin use was also not associated with 
improved survival when the analyses were stratified by tumour p53 (wild-type 
HR=1.31, 95% CI 0.67-2.56 versus aberrant HR=0.80, 95% CI 0.52-1.24), HMGCR 
(HMGCR-high HR=0.69, 95% CI 0.40-1.18 versus HMGCR-low HR=1.10, 95% CI 
0.66-1.84), and KRAS (wild-type HR=0.73, 95% CI 0.44-1.19 versus mutant 
HR=1.21, 95% CI 0.70-2.21) status.  
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Conclusion 
Statin use was not associated with improved survival either independently or 
when stratified by potential mevalonate pathway biomarkers in this population-based 
cohort of colon cancer patients. 
 
KEYWORDS 
Hydroxymethylglutaryl-CoA reductase inhibitors; Tumour suppressor protein p53; 
HMGCR protein; KRAS; Colonic neoplasms; Survival.  
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INTRODUCTION 
Statins are commonly prescribed lipid lowering medications that inhibit the 
enzyme 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGCR).(Ng et al, 
2011) In addition to their cholesterol lowering action they may have pleiotropic anti-
cancer effects through inhibition of the mevalonate pathway.(Bardou et al, 2010; 
Thurnher et al, 2012) However observational data assessing the association 
between post-diagnostic statin use and colorectal cancer survival lacks 
consistency.(Ng et al, 2011; Mace et al, 2013; Cardwell et al, 2014a; Krens et al, 
2014; Hoffmeister et al, 2015; Kim et al, 2015; Lim et al, 2015; Zanders et al, 2015) 
As a robust association has yet to be identified, caution is required in proceeding 
with clinical trials assessing the role of statins as novel adjuvant agents. In addition, 
colorectal tumours are known to display significant molecular heterogeneity.(Ogino 
et al, 2012) A molecular pathological epidemiology approach is therefore required to 
determine if the potential anti-cancer effect of statins is confined to specific molecular 
subgroups.(Ogino et al, 2011) Candidate mevalonate pathway biomarkers that may 
differentiate tumours more likely to respond to statin therapy include HMGCR, p53 
and KRAS. 
The seminal work by Freed-Pastor et al implicates the mevalonate pathway 
as a potential therapeutic target for tumours bearing mutations in TP53.(Freed-
Pastor et al, 2012) They demonstrated that statins were able to reverse the 
malignant phenotype of p53 mutant but not p53 wild-type breast cancer cells in vitro. 
Similarly, an in vivo breast cancer study demonstrated that the anti-proliferative 
effect of statins was limited to tumours that overexpressed HMGCR.(Bjarnadottir et 
al, 2013) Finally, RAS signaling may be inhibited by statin-induced depletion of 
downstream isoprenoids required for posttranslational prenylation of small GTPases 
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like ras and rho.(Bardou et al, 2010; Ng et al, 2011; Thurnher et al, 2012) Prenylation 
of k-ras makes the protein lipophilic and ensures translocation to the cell membrane 
where it can exert its proliferative effects.(Konstantinopoulos et al, 2007; Krens et al, 
2014) Based on this hypothesis the effect of statins on colorectal cancer survival 
may differ according to KRAS gene mutation status.(Ng et al, 2011) The aim of this 
study was therefore to assess the interaction between statin use, the potential 
mevalonate pathway biomarkers p53, HMGCR and KRAS, and survival in a 
population-based cohort study of patients with stage II and III colon cancer. 
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METHODS 
Study cohort 
The Northern Ireland Cancer Registry was used to identify 1,426 stage II and 
III colon cancer patients undergoing surgical resection between 2004 and 2008 
(Figure 1). Rectal cancers were excluded as neoadjuvant radiotherapy could 
potentially alter tumour expression profiles. Ethical approval through the Northern 
Ireland Biobank (NIB ref. 13-0087) permitted retrieval of formalin fixed, paraffin-
embedded (FFPE) tissue blocks for patients within two of the five regional Health 
and Social Care trusts. For this molecular pathological epidemiology study, the final 
cohort was subsequently restricted to only include patients within the biobank remit 
(n=740, 51.9%). These patients were representative of the overall Northern Ireland 
cohort with respect to age, sex, stage and adjuvant chemotherapy receipt 
(Supplementary Table 1). 
Clinicopathological variables and follow-up 
The Clinical Oncology Information System (COIS), a prospective electronic 
record of cancer patient management, was used to collect clinical variables including 
adjuvant chemotherapy use, prescription medication use, family history of colorectal 
cancer and Eastern Cooperative Oncology Group (ECOG) performance status. This 
process was supplemented by a manual chart review when insufficient information 
was recorded on COIS or no record was present. Pathological variables were 
retrieved from full pathology reports. Occurrence and cause of death were assessed 
via data linkage to the Northern Ireland Registrar General’s Office (follow-up 
censored 31st December 2013). Colorectal cancer-specific deaths were defined as 
those with an underlying cause of death International Classification of Disease code 
C18, C19, C20 (anus) and/or C26 (other and ill-defined digestive organs). 
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Drug exposure assessment 
Statin exposure (user versus non-user) based on current prescription 
medications was assessed at a single perioperative time point for all patients. When 
medication information was available on COIS this time point was the initial post-
operative oncology review. When medication information was not available on COIS 
statin exposure was determined from the post-operative hospital discharge letter. 
Information on medication dosage was not consistently recorded on COIS and 
therefore not considered. Information on aspirin exposure was also assessed using 
these methods. Our research group has previously demonstrated that 98.5% of 
aspirin prescriptions after colorectal cancer diagnosis in the United Kingdom (UK) 
are for low-dose (75mg) aspirin.(Cardwell et al, 2014b) Aspirin exposure in this study 
is therefore considered representative of low-dose aspirin. 
 
Tumour molecular analysis 
FFPE blocks were retrieved for 89.3% of the cohort (661 of 740). Three 
1.0mm diameter tissue cores were extracted from representative areas within donor 
blocks and inserted into recipient blocks using a manual tissue arrayer (Estigen, 
Tartu, Estonia) as described previously.(Zhang et al, 2003; Boyle et al, 2014) The 
immunohistochemistry methods for p53 (DO-7 antibody clone to p53, Dako UK Ltd, 
Ely, UK - catalogue number M7001) and HMGCR (Atlas Antibodies AB, Stockholm, 
Sweden - catalogue number HPA008338) staining are described in the 
Supplementary Methods. QuPath (Queen’s University Belfast, Northern Ireland) 
image analysis software facilitated digital immunoscoring (Supplementary Methods). 
A H-score was calculated based on the extent and intensity of cytoplasmic or nuclear 
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staining where appropriate (H-score = 3 x % of strongly staining cytoplasm + 2 x % 
of moderately staining cytoplasm + 1 x % of weakly staining cytoplasm, giving a 
range of 0 to 300).(McCarty et al, 1986) 
A three-tier scoring system was applied to differentiate normal (non-extreme) 
from aberrant (extreme positive or extreme negative) patterns of p53 expression 
(Figure 2). Cores were designated as extreme negative if there was confluent 
negative staining within the represented population of tumour nuclei. Diffuse strong 
positivity was considered representative of extreme positive expression and 
intermediate heterogeneous expression was considered a non-extreme (normal) 
pattern of staining.(Boyle et al, 2014) Selection and validation of the p53 cut points 
are described in the Supplementary Methods. HMGCR H-scores were categorised 
into tertiles for prognostic analyses and dichotomised around the median value for 
survival analyses that tested the interaction between statin use and HMGCR 
expression. Representative images of HMGCR expression are shown in 
Supplementary Figure 1. Based on these methods the final p53 and HMGCR 
categories were determined using the median of the three available H-scores for 
each case. 
 Detailed methods for DNA extraction, KRAS mutation analysis and 
microsatellite instability (MSI) status using commercially available kits are provided 
as Supplementary Methods. Briefly KRAS mutation status was assessed using 
previously described methods for the ColoCarta Panel (Agena Bioscience, Hamburg, 
Germany)(Fumagalli et al, 2010) while MSI status was determined using five 
mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27). 
 
Statistical analysis 
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All statistical analysis was performed using Stata 13 (StataCorp, College 
Station, TX, USA). The chi-square test was used to compare characteristics between 
statin users and non-users. The primary outcome of this study was colorectal 
cancer-specific survival and the secondary outcome was overall survival. The 
association between statin use and survival was assessed in the whole cohort and 
then in analyses stratified by biomarker status. Only cases with information on statin 
exposure (known user versus known non-user) were included in the former analysis. 
Only cases with available exposure information and tissue for biomarker assessment 
were included in the subsequent stratified analyses. Other missing categorical data 
were coded as unknown. 
Survival analysis was performed using the Cox proportional hazards model to 
calculate hazard ratios (HRs) and associated 95% confidence intervals. The 
multivariable models for colorectal cancer-specific survival adjusted for age, gender, 
year of diagnosis, grade, MSI status, Eastern Cooperative Oncology Group 
performance status, family history of colorectal cancer, adjuvant chemotherapy use, 
stage and aspirin use.. In addition to the these variables, the overall survival 
multivariable model also adjusted for Charlson Comorbidity Index score as a 
continuous variable.(Khan et al, 2010) Analyses were stratified by biomarker status.  
Interaction terms for statin use and p53, HMGCR, or KRAS were then included in the 
Cox model and the Wald test was used to assess for statistical interaction. 
Sensitivity analysis was performed using complete-case data (cases with missing 
data were excluded). All P values were two-sided and a value <0.05 was considered 
statistically significant. 
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RESULTS 
Patients 
Information on prescription medication use was available for 91.9% (n=680) of 
patients in this population-based cohort study. Overall, 25.3% (n=172) used statins. 
Compared to those with available information on medication use, patients with no 
information on medication use were older and more likely to be diagnosed in the 
earlier years of the study. However, there was no difference in stage, grade of 
tumour differentiation or MSI status (Supplementary Table 2). After a mean follow-up 
of 5.7 years (range 0-10) there were 299 all-cause and 212 colorectal cancer-
specific deaths among these patients.  
 
Statin use and survival  
Table 1 summarises the baseline characteristics between statin users and 
non-users. Statin users were more likely to be older, male, and diagnosed later in the 
cohort compared to statin non-users. Statin users were also more likely to 
concomitantly use aspirin. There were a smaller proportion of MSI-high tumours 
among statin users but the proportion of patients with unknown MSI status was 
higher in statin non-users. However there was no difference in tumour differentiation 
grade, stage or the proportion of patients receiving adjuvant chemotherapy between 
users and non-users. There was also no difference in the proportion of right-sided 
tumours in statin users compared to non-users (58.1 versus 56.1%). 
Statin use at the time of diagnosis was not associated with a significant 
reduction in colorectal cancer-specific (adjusted HR=0.91, 95% CI 0.64-1.28) or 
overall mortality (adjusted HR=0.83, 95% CI 0.61-1.12) compared to non-use (Table 
2). 
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Immunohistochemical expression of p53 
In total n=361 (59.9%) tumours demonstrated an aberrant pattern of p53 
immunostaining (extreme positive or extreme negative). The proportion of tumours 
with aberrant patterns of p53 immunostaining was similar between statin users and 
statin non-users (59.1% versus 62.0%, P=0.52). Compared to wild-type p53 
expression, aberrant p53 immunostaining was associated with a 53% increase in 
hazard for unadjusted colorectal cancer-specific mortality (HR=1.53, 95% CI 1.13-
2.09). However, this association was attenuated when potential confounding 
variables were included in the multivariable model (adjusted HR=1.38, 95% CI 0.97-
1.95, Table 2).  
In stratified analysis there was no evidence that the association between 
statin use and colorectal cancer-specific survival differed by p53 immunostaining 
patterns (wild-type adjusted HR=1.31, 95% CI 0.67-2.56 versus aberrant adjusted 
HR=0.80, 95% CI 0.52-1.24). Similar results were observed for overall survival 
(Table 3). 
 
HMGCR immunohistochemical expression 
Statin users were more likely to have tumours in the highest HMGCR tertile 
compared to non-users (43.7% versus 30.8%, P=0.01). As shown in Table 2 
however, there was no evidence that higher levels of HMGCR expression were 
associated with significantly better colorectal cancer-specific or overall survival 
(adjusted P for trend=0.18 and 0.12 respectively).  
There was no evidence of significant associations with colorectal cancer-
specific survival among statin users compared to non-users when the cohort was 
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stratified by tumour HMGCR expression level, although the direction of hazard ratios 
did differ (HMGCR-high adjusted HR=0.69, 95% CI 0.40-1.18, P=0.17 versus 
HMGCR-low adjusted HR=1.10, 95% CI 0.66-1.84). Similarly, there was no evidence 
of a differential benefit for overall survival in statin users compared to non-users 
when the cohort was stratified by HMGCR status (Table 3). 
 
KRAS mutations 
KRAS mutation status (mutant versus wild-type) was available for 99.2% of 
these samples with extracted DNA (594 of 599). Statin users had slightly less KRAS 
mutant tumours compared to statin non-users although the difference was not 
statistically significant (34.0% versus 40.2%, P=0.17). Compared to wild-type KRAS, 
the presence of a KRAS mutation was not associated with significantly worse 
colorectal cancer-specific survival (adjusted HR=1.12, 95% CI 0.82-1.53, Table 2).  
There was no evidence of an improvement in colorectal cancer-specific 
survival among statin users compared to non-users when the cohort was stratified by 
KRAS mutation status, although again the direction of effect differed between wild-
type and mutant KRAS tumours (KRAS wild-type adjusted HR=0.73, 95% CI 0.44-
1.19 versus KRAS mutant tumour adjusted HR=1.21, 95% CI 0.70-2.21). Similar 
non-significant results were observed for overall survival (Table 3). 
 
Sensitivity analysis 
In general the associations described above were not markedly altered when 
a complete case dataset (n=372) was used (Table 4). There was some evidence 
though that statin use was associated with improved colorectal cancer-specific 
survival in tumours that had higher levels of HMGCR expression (HMGCR-high 
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adjusted HR=0.51, 95% CI 0.26-0.97, P=0.04 versus HMGCR-low adjusted 
HR=0.92, 95% CI 0.45-1.87, P for interaction=0.05). Previously observed null 
associations by KRAS status and p53 expression remained.  All associations 
became attenuated in analyses evaluating overall survival.   
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DISCUSSION 
In this population-based cohort study of stage II and III colon cancer, 
perioperative statin prescription was not associated with significantly improved 
colorectal cancer-specific survival. Similarly, statin use was not associated with 
better colorectal cancer-specific or overall survival when the cohort was stratified by 
tumour biomarkers related to the mevalonate pathway.  
The hazard ratio for the association between statin use and cancer-specific 
survival in this cohort was similar to that reported in a recent meta-analysis of 
colorectal cancer observational studies.(Gray et al, 2016) The pooled estimate from 
four studies assessing post-diagnostic statin use was non-significant despite 
including over 19,000 patients. It also suggests that the effect of any association is 
only likely to be moderate at best (pooled HR=0.84, 95% CI 0.68-1.04). Despite 
optimistic pre-clinical data these findings confirm the need to evaluate biomarkers 
that may identify tumours more likely to respond to the potential anti-cancer effects 
of statins.  
This is the first study to assess the interaction between statin use and 
HMGCR expression in colon cancer. Statin users had a higher proportion of tumours 
in the highest HMGCR tertile although statin-induced inhibition of the mevalonate 
pathway is known to trigger a marked increase in the production of inactive HMGCR 
in vitro.(Goldstein & Brown, 1990; Bengtsson et al, 2014) In the main analysis there 
was no evidence that statin users had better survival compared to non-users in 
tumours with higher levels of HMGCR expression. However, in the complete-case 
subgroup analysis, which excluded cases with any missing data, statin use was 
associated with better cancer-specific survival in tumours with higher levels of 
HMGCR expression. This result should be interpreted with caution though, as 
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multiple hypotheses were tested. Further exploration in additional molecular 
pathological epidemiology cohorts should be considered, as the complete-case 
subgroup analysis results are in line with an in vivo breast cancer study which 
suggests that statins may have an anti-proliferative effect in tumours that 
overexpress HMGCR.(Bjarnadottir et al, 2013) 
Overexpression of HMGCR has been proposed to be prognostic in a number 
of malignancies including breast(Borgquist et al, 2008; Brennan et al, 2011) and 
epithelial ovarian cancer.(Brennan et al, 2010) However, a recent population-based 
breast cancer cohort study failed to demonstrate that overexpression of HMGCR 
was associated with better survival.(Gustbée et al, 2015) Similarly, overexpression of 
HMGCR was not associated with improved survival after adjusting for confounding 
variables in colorectal cancer cases within the Malmö Diet and Cancer 
Study.(Bengtsson et al, 2014) The present study largely corroborates this finding.  
To the best of the authors’ knowledge this is the first study to assess the 
interaction between statin use, p53 expression and survival in patients with colon 
cancer. A significant interaction was not identified in this instance but further work is 
required as TP53 mutation status was not directly assessed. Missense TP53 
mutations result in stabilization of an inactive form of p53 resulting in nuclear 
accumulation and a correlation with the aberrant positive pattern of expression.(Kaye 
et al, 2010; McCluggage et al, 2011) Only more recently has it been widely 
appreciated that the aberrant negative pattern of p53 staining is a distinct entity and 
not part of the spectrum of wild-type staining.(Boyle et al, 2014) This pattern of 
staining may be attributed to a null TP53 mutation resulting in complete absence of 
the detectable protein.(Köbel et al, 2010) Importantly though, these patterns should 
be viewed as a spectrum of functional protein status rather than as a surrogate for 
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TP53 mutation status as epigenetic silencing may also contribute to aberrant 
negative expression.(Kaye et al, 2010; Boyle et al, 2014) On this basis, mevalonate 
pathway gene-expression upregulation associated with mutant p53(Freed-Pastor et 
al, 2012) may be specific to mutations of TP53 rather than to alternate 
circumstances resulting in aberrant expression of the protein. Future studies should 
therefore assess the interaction between the presence of TP53 mutations, statin use 
and colon cancer survival before excluding the potential relevance of this biomarker. 
Finally, statin use was not associated with improved colorectal cancer-specific 
or overall survival when the cohort was stratified by KRAS mutation status. This 
finding is consistent with results from a cohort of 394 patients enrolled in a 
chemotherapy clinical trial (CALGB 89803) (Ng et al, 2011) and 1209 patients within 
a German population-based colorectal cancer cohort.(Hoffmeister et al, 2015) 
Similarly, statin use was not associated with improved progression free survival in 
cetuximab treated metastatic colorectal cancer patients within the CAIRO2 trial, 
irrespective of KRAS mutation status.(Krens et al, 2014) The median progression 
free survival was also similar between the statin and placebo arms of a subgroup of 
83 patients with KRAS mutant tumours in a randomized controlled trial of 
XELIRI/FOLFIRI +/- simvastatin in patients with metastatic colorectal cancer.(Lim et 
al, 2015)  
A major strength of this study is the inclusion of population-representative 
colon cancer patients. Application of a precise, automated and validated digital 
immunoscoring system also ensures robust immunoexpression data that is highly 
reproducible. As with all observational studies however there may be residual 
confounding that we were not able to control. A more specific limitation is that data 
on statin prescription was also only available at a single perioperative time point and 
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this may not reflect changes in post-diagnostic use.(Paleari et al, 2016) However, a 
similar European colorectal cancer cohort demonstrated 88% concordance between 
baseline and long-term statin use.(Hoffmeister et al, 2015) Statin use at this time 
could also alter tumour behavior as it has previously been reported that pre-
diagnostic statin users were less likely to develop KRAS wild-type tumours.(Lee et 
al, 2011) In the current study the opposite association (non-significant) was observed 
with a lower proportion of KRAS mutant tumours amongst statin users. Importantly 
though, assessing medication use at a fixed time point excludes immortal time 
bias.(Lévesque et al, 2010) The assessment of Ras status was limited to exons 2 
and 3 of KRAS in this study. Misclassification could occur for other mutations of 
KRAS or NRAS although overall these mutations are uncommon (<3%) and it is  
unlikely that this would greatly alter the stratified analysis. 
A further limitation is that information on the type and dose of statin prescribed 
was not available. It has previously been hypothesised that the potential anti-cancer 
effect of statins is restricted to lipophilic statins.(Ahern et al, 2014) Also, the serum 
statin concentrations achieved with cardiovascular protective doses of the 
medication (e.g. simvastatin 40mg) may not be sufficient to induce the anti-cancer 
effects observed in preclinical studies.(Lim et al, 2015) Finally, despite being 
population-based this study lacks power to definitively investigate the interaction 
between the proposed mevalonate pathway biomarkers, statin use and colon cancer 
survival. 
In summary, statin use was not associated with better survival in this 
population-based colon cancer cohort study. In keeping with previous studies a 
survival benefit for statin use was not apparent after stratification by tumour KRAS 
mutation status. Similar results were also observed for p53 immunohistochemical 
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status but additional studies should assess TP53 mutation status as a potential 
biomarker. There was some evidence of a difference in association between statin 
use and colon cancer survival by tumour HMGCR expression. In general though, this 
finding was inconsistent and requires further investigation in additional large studies. 
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FIGURE LEGEND 
 
Figure 1. Selection of stage II and III colon cancer (adenocarcinoma) patients and 
samples. Abbreviation: ICD – International Classification of Disease; NIB – Northern 
Ireland Biobank.  
 
Figure 2. p53 immunohistochemistry in colon cancer tissue microarrays and 
associated markup for digital immunoscoring using QuPath image analysis software. 
Detected cells are color-coded according to their classification: green = non-tumour; 
blue = negatively staining tumour; yellow = weakly staining tumour; orange = 
moderately staining tumour; red = strongly staining tumour. (A) Original core from a 
tumour demonstrating aberrant negative p53 immunostaining. (B) Original core from 
a tumour deomonstrating non-extreme (normal) p53 immunostaining. (C) Original 
core from a tumour demonstrating aberrant positive p53 immunostaining. (D) QuPath 
cellular markup in the aberrant negative p53 core. (E) QuPath cellular markup in the 
non-extreme (normal) p53 core. (F) QuPath cellular markup in the aberrant positive 
p53 core.  
